Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Circio Holding

Less than 1K followers

CRNA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview
Investor consensus

Circio Holding is a pharmaceutical company. The company's specialist expertise is found in targeted immunotherapy used in the treatment of cancer patients. The company's operations consist of research and development and the medicines are sold under separate brands. Several partnerships in the market have been entered into to strengthen cooperation in the development of new immunotherapy. The company was founded in 2010 and is headquartered in Lysaker.

Read more
Market cap
-
Turnover
-
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
All
Press releases
ShowingAll content types
Regulatory press release12/3/2025, 2:23 PM

Corr*: Atlas Holdings for CIRCIO

Circio Holding
Regulatory press release12/3/2025, 11:36 AM

CRNA: Atlas Holdings for CIRCIO

Circio Holding
Regulatory press release11/25/2025, 2:22 PM

CRNA: Atlas Holdings for CIRCIO

Circio Holding

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release11/24/2025, 6:00 AM

Circio presents data that further strengthens and broadens its circVec circular RNA expression platform

Circio Holding
Regulatory press release11/20/2025, 4:28 PM

Shareholding disclosure - Nordnet AB (publ)

Circio Holding
Regulatory press release11/20/2025, 1:38 PM

Shareholding disclosure - Nordnet AB (publ)

Circio Holding
Regulatory press release11/19/2025, 3:53 PM

Shareholding disclosure - Nordnet AB (publ)

Circio Holding
Regulatory press release11/19/2025, 3:32 PM

CRNA: Atlas Holdings for CIRCIO

Circio Holding
Regulatory press release11/19/2025, 3:27 PM

Shareholding disclosure - Nordnet AB (publ)

Circio Holding
Regulatory press release11/19/2025, 12:04 PM

Shareholding Disclosure - Nordnet

Circio Holding
Regulatory press release11/18/2025, 4:11 PM

Shareholding disclosure - Nordnet AB (publ)

Circio Holding
Press release11/17/2025, 1:00 PM

Circio issues invitation to R&D and corporate update webcast on 24 November 2025

Circio Holding
Regulatory press release11/3/2025, 7:13 AM

Corr: Atlas Holdings for CIRCIO

Circio Holding
Regulatory press release10/30/2025, 10:02 AM

Corr: Atlas Holdings for CIRCIO

Circio Holding
Regulatory press release10/30/2025, 7:04 AM

CRNA: Atlas Holdings for CIRCIO

Circio Holding
Press release10/22/2025, 8:50 AM

Analyst Group: Analyst Group intervjuar Circios VD Erik Digman Wiklund

Circio Holding
Regulatory press release10/19/2025, 7:45 PM

Circio Holding ASA – Bond conversion and additional trading restrictions

Circio Holding
Regulatory press release10/17/2025, 2:39 PM

Circio Holding ASA: Requested Conversion of Convertible Bonds

Circio Holding
Regulatory press release10/15/2025, 9:14 AM

Circio Holding ASA: Requested Conversion of Convertible Bonds

Circio Holding
Regulatory press release10/8/2025, 5:00 AM

Circio presents comprehensive circVec in vivo data package demonstrating 40-fold improvement over conventional AAV gene delivery at ESGCT 2025

Circio Holding
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.